Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia

Table 1 Sociodemographic, clinical, and biomarker variables in the final analysis set (n = 115) and in the respective comparison group (max. n = 956; actual group size for each variable is the maximal N available for the comparison group)

Variable	Final analysis sample (n =115) MCI-stable + MCI-AD	Comparison group (n = 956)		P value
Variable	Final analysis sample (n =115) MCI-stable + MCI-AD	Group size (n)	All other MCI with data available	P value
Age	65.7 ± 9.0	956	67.1 ± 8.6	ns
Sex (male = 1)	1.4 ± 0.5	956	1.5 ± 0.5	ns
education	9.5 ± 1.9	956	9.5 ± 1.9	ns
MMSE	27.0 ± 2.1	956	27.2 ± 2.2	ns
MADRS	7.4 ± 5.6	908	7.8 ± 6.2	ns
B-ADL	2.5 ± 1.5	903	2.3 ± 1.4	ns
CDR-sb	1.8 ± 1.1	956	1.5 ± 1.0	0.01
CERAD-DR-WL	4.8 ± 2.3	956	5.0 ± 2.3	ns
Hippocampal volume	4450 ± 672	368	4511 ± 653	ns
Aβ42	749 ± 300	292	751 ± 353	ns
Aβ40	9654 ± 2732	268	9684 ± 3030	ns
Aβ ratio	0.08 ± 0.03	266	0.08 ± 0.04	ns
Total tau	411 ± 251	284	446 ± 304	ns
Phosphorylated tau	61 ± 30	289	67 ± 36	ns

Data are given as mean ± standard deviation
There is no significant difference between the groups with the exception of CDR-sb which is not clinically relevant
P values were uncorrected for multiple comparisons
Aβ40 amyloid-beta_1–40, Aβ42 amyloid-beta_1–42, AD Alzheimer’s disease, B-ADL Bayer activities of daily living, CDR-sb Clinical Dementia Rating–sum-of-boxes, CERAD-DR-WL Consortium to Establish a Registry of Dementia–delayed recall word list, MADRS Montgomery-Asberg Depression Rating Scale, MCI cognitive impairment, MMSE Mini-Mental State Examination, ns not significant

ISSN: 1758-9193